Celecoxib News and Research

RSS

Animi-3 may offer hope for rheumatoid arthritis

Animi-3, a prescription medication from PBM Pharmaceuticals, Inc., contains ingredients that may have a beneficial, protective effect in inflammatory diseases such as rheumatoid arthritis (RA).

7 Apr 2005

Patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain

Researchers from the Altoona Arthritis and Osteoporosis Center have announced that data presented at the 24th Annual Scientific Meeting of the American Pain Society suggest that patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain.

3 Apr 2005

International expert group discusses alternatives to COX-2 inhibitors

International group of pain specialists meets to develop recommendations for the treatment of chronic moderate-to-severe pain in the wake of the global withdrawal of rofecoxib (Vioxx) and concerns regarding use of other COX-2 inhibitors.

7 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study.

22 Feb 2005

Vioxx could have caused 140000 excess cases of coronary heart disease in the USA since 1999

The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.

24 Jan 2005

Warfarin combined with NSAIDs or COX-2 inhibitors increased risk of upper gastrointentinal hemorrhage

Patients taking warfarin at the same time as selective COX-2 inhibitors or nonselective NSAIDs have an increased risk of hospitalization for upper gastrointestinal (GI) hemorrhage, according to Canadian researchers analyzing health care databases.

24 Jan 2005

More studies on risks and benefits of COX-2 inhibitors

A group of studies published in the January 24 issue of Archives of Internal Medicine add to the growing body of medical literature about the cardiovascular risks that may be associated with the class of pain-relieving drugs known as COX-2 inhibitors.

24 Jan 2005

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.

17 Jan 2005

Trial of naproxen and celecoxib suspended

Use of study drugs in a large, federally funded Alzheimer prevention trial has been suspended following a decision by the study's leadership on Dec. 17, 2004.

9 Jan 2005

Zinc treatment may help prevent esophageal and oral cancers

Cancer researchers at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have found that zinc treatment may help prevent esophageal and oral cancers in those individuals at high risk.

9 Jan 2005

Lessons learned from troubles with COX-2 inhibitors

One of the nation’s leading cardiovascular medical researchers has issued a call for less aggressive direct-to-consumer advertising and better safety assurances of medications in a special article posted online by JAMA because of its relevance to the recent withdrawals and warning labels on the pain-relieving drugs known as COX-2 inhibitors.

28 Dec 2004

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

Arthritis drug caution advised by New Zealand experts

An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.

21 Dec 2004

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

Patients who are taking Celebrex, Bextra and Arcoxia should make a non-urgent appointment with their GP to review their treatment. Patients who have established heart disease or who are at high risk of stroke will have their treatment changed.

21 Dec 2004

Potential safety risks with Celebrex

The Australian Therapeutic Goods Administration (TGA) has consulted today with the Chairs of its peak advisory committees, the Australian Adverse Drug Reactions Committee (ADRAC) and the Australian Drug Evaluation Committee (ADEC), about the latest research into the safety of the arthritis drug, Celebrex.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Celecoxib may regulate a cell's use of estrogen - might help explain the drug's anticancer properties

Six months of treatment with celecoxib (Celebrex) in women at risk of developing breast cancer results in the reduction of estrogen receptor expression in breast cells, a research team at The University of Texas M. D. Anderson Cancer Center has found.

13 Dec 2004

Greater risk of heart attack associated with Vioxx than Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.

8 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Celecoxib News and Research

Animi-3 may offer hope for rheumatoid arthritis

Patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain

International expert group discusses alternatives to COX-2 inhibitors

Celebrex provides a two pronged attack against prostate cancer

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Vioxx could have caused 140000 excess cases of coronary heart disease in the USA since 1999

Warfarin combined with NSAIDs or COX-2 inhibitors increased risk of upper gastrointentinal hemorrhage

More studies on risks and benefits of COX-2 inhibitors

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

Trial of naproxen and celecoxib suspended

Zinc treatment may help prevent esophageal and oral cancers

Lessons learned from troubles with COX-2 inhibitors

Public health advisory for the use of non-steroidal anti-inflammatory drug products

Arthritis drug caution advised by New Zealand experts

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

Potential safety risks with Celebrex

Celebrex suspension

Celecoxib may regulate a cell's use of estrogen - might help explain the drug's anticancer properties

Greater risk of heart attack associated with Vioxx than Celebrex

New insight into anticoagulation therapies

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News